Table 1.

Percent distribution of sociodemographic characteristics, vital status, and disease stage by amenability levels in study population, 11 SEER registries, patients ages ≥20 years, diagnosed from 1995 to 1999 with follow-up through 2004

Total (n = 580,225)Nonamenable* (n = 142,488)Partly amenable (n = 142,596)Mostly amenable (n = 295,141)
Year of diagnosis
    199519.019.519.118.7
    199619.419.819.519.2
    199720.120.020.120.1
    199820.520.420.620.5
    199921.020.320.721.5
Age at diagnosis (y)
    20-343.81.83.25.1
    35-4913.98.913.316.6
    50-6428.828.227.129.9
    65-7940.146.838.837.4
    ≥8013.514.317.711.0
Stage at diagnosis
    Localized47.614.229.472.5
    Regional21.928.426.616.4
    Distant19.144.222.45.4
    Unknown stage11.513.221.65.8
Gender
    Male50.256.650.147.1
    Female49.843.449.952.9
Race/ethnicity
    African American9.511.09.29.0
    American Indian/Alaska Native0.40.40.40.3
    Asian/Pacific Islander7.18.57.76.2
    Hispanic7.87.48.07.8
    White75.272.874.776.7
Residential county poverty concentration
    Least poor (<10%)47.145.847.047.7
    Medium poor (10-19%)51.352.551.350.7
    Poorest (≥20%)1.61.71.71.6
Vital status (as of December 31, 2004)
    Deceased (cause of death cancer)36.478.640.014.2
    Deceased (cause of death other than cancer)13.410.316.413.5
    Alive50.211.143.672.3
  • *Low-amenability cancer sites (International Classification of Diseases, Ninth Revision code) have 5-y RSRs <40% and include pancreas (157), pleura (163), liver and intrahepatic bile ducts (155). Other specified leukemia (207), esophagus (150), trachea, lung and bronchus (162), monocytic leukemia (206), gallbladder and extrahepatic bile ducts (156), stomach (151), brain (191), myeloid leukemia (205), uterus, part unspecified (179), hypopharynx (148), myeloma (203), and retroperitoneum and peritoneum (158).

  • Medium-amenability cancer sites (International Classification of Diseases, Ninth Revision code) have 5-y RSRs of 40% to 69% and include ovary (183), lymphosarcoma and reticulosarcoma (200), floor of mouth (144), small intestine (152), endocrine glands and related structures excluding thyroid (194), nose, nasal cavities, and middle ear (160), thymus, heart, and mediastinum (164), trachea and oropharynx (146.3-146.9), tonsil (146.0-146.2), tongue (141), mouth excluding gum and floor and including unspecified parts of mouth (145), nasopharynx (147), gum (143), colon excluding rectum (153), larynx (161), rectum, rectosigmoid junction, and anus (154), kidney and other and unspecified urinary organs (189), lymphoid leukemia (204), connective and soft tissue excluding heart (171), and other malignant neoplasms of lymphoid and histiocytic tissue (202).

  • High-amenability cancer site (International Classification of Diseases, Ninth Revision code) have 5-y RSRs ≥70% and include other nonepithelial skin (173), bone and articular cartilage (170), vagina, vulva, and other and unspecified female genital organs (184), nervous system excluding brain and including unspecified parts (192), cervix uteri (180), penis and other male genital organs (187), major salivary glands (142), male breast (175), eye (190), bladder (188), Hodgkin's lymphoma (201), corpus uteri (182), female breast (174), placenta (181), melanoma of the skin (172), lip (140), testis (186), thyroid (193), and prostate (185).